Michael Cappelli, MD
Radiation Oncology · Demopolis, ALNPI 1194702928
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $527 and has fallen 85.1% since, to $78 in 2025. That places this record below the midpoint for radiation oncology clinicians in AL, where the typical reported total is $993.
Across 59 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$190
- Daiichi Sankyo Inc.$166
- Merck$88
- Sanofi$67
- Sobi, Inc$65
- Eisai Inc.$62
- plus $544 from 21 others
What the payments were for
- Food & beverage$1,182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $190 |
| Daiichi Sankyo Inc. | 8 | $166 |
| Merck | 5 | $88 |
| Sanofi | 3 | $67 |
| Sobi, Inc | 2 | $65 |
| Eisai Inc. | 4 | $62 |
| Pfizer | 3 | $56 |
| Pharmacosmos Therapeutics Inc. | 3 | $48 |
| Novocure Inc. | 1 | $45 |
| Incyte Corporation | 2 | $35 |
| Amgen | 2 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Deciphera Pharmaceuticals Inc. | 1 | $33 |
| AMAG Pharmaceuticals, Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $22 |
| Coherus Oncology, Inc. | 1 | $21 |
| Beigene USA, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Seagen Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Elekta, Inc. | 1 | $10 |
How this compares
$1,182 in reported general payments places this provider in the 50th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $473 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Demopolis
- Alexander WhitleyMontgomery$441K
- Drexell BoggsBirmingham$35K
- Christopher JahrausAlabaster$28K
- Christopher WilleyBirmingham$13K
- Adam KoleBirmingham$11K
- William HixsonFairhope$10K
- John GleasonHuntsville$9K
- Andrew McDonaldBirmingham$8K
- Hoyt ChildsHuntsville$7K
- James TuckerTuscaloosa$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.